<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5145">
  <stage>Registered</stage>
  <submitdate>26/09/2013</submitdate>
  <approvaldate>26/09/2013</approvaldate>
  <nctid>NCT01953926</nctid>
  <trial_identification>
    <studytitle>An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification</studytitle>
    <scientifictitle>An Open-label, Multicenter, Multinational, Phase 2 Study Exploring the Efficacy and Safety of Neratinib Therapy in Patients With Solid Tumors With Activating HER2, HER3 or EGFR Mutations or With EGFR Gene Amplification.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-002872-42</secondaryid>
    <secondaryid>PUMA-NER-5201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Solid Tumors</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Neratinib
Treatment: drugs - Paclitaxel
Treatment: drugs - Fulvestrant

Experimental: Neratinib monotherapy - Neratinib monotherapy in any HER2 mutated Cancers excluding Hormone positive breast cancers and bladder cancers

Experimental: Neratinib and Paclitaxel - Neratinib and Paclitaxel in HER2 mutated bladder cancers

Experimental: Neratinib and Fulvestrant - Neratinib and Fulvestrant in HER2 mutated hormone positive breast cancers Interventions


Treatment: drugs: Neratinib
Neratinib 240 mg orally, once daily with food, continuously in 28 day cycles

Treatment: drugs: Paclitaxel
80mg/m^2 IV on Days 1, 8, and 15 of every 4 week cycle

Treatment: drugs: Fulvestrant
500 mg administered as two 5 mL injections on Days 1, 15 of the first month, then Day 1 of every 4 week cycle

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Objective Response Rate at 8 weeks (ORR8) - The primary objective of this study is to determine the objective response rate at 8 weeks (ORR8) following treatment with neratinib in patients with HER2 (ERBB2), HER3 (ERBB3) or EGFR mutation-positive solid tumors or with EGFR gene amplification.</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR) - Secondary Outcome Measure Description is to determine the best confirmed overall response rate (ORR) with neratinib in patients with HER2, HER3 or EGFR mutation-positive solid tumors or with EGFR gene amplification.</outcome>
      <timepoint>Estimated 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival (PFS)</outcome>
      <timepoint>Estimated 18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Benefit Rate (CBR) - Clinical benefit rate (CBR) is defined as the percentage of patients with complete response (CR) + partial response (PR) + stable disease (SD) =16 weeks from the date of enrollment</outcome>
      <timepoint>16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DOR) - Duration of response (DOR) is defined as the time from which measurement criteria are met for CR or PR (whichever status is recorded first) until the first date of documented disease progression.</outcome>
      <timepoint>Estimated 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival (OS)</outcome>
      <timepoint>Estimated 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety (Adverse Events [AEs] and Serious Adverse Events [SAEs])</outcome>
      <timepoint>From consent through 28 days following treatment completion (estimated 6 months)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed cancers for which no curative therapy exists.

          -  Documented HER2 mutation.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior treatment with any pan-HER TKI (eg, lapatinib, afatinib, dacomitinib,
             neratinib).

          -  Patients who are receiving any other anticancer agents.

          -  Symptomatic or unstable brain metastases.

          -  Women who are pregnant or breast-feeding.

        Note: There are additional inclusion and exclusion criteria. The study center will
        determine if you meet all of the criteria.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>30/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>292</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <postcode>8006 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Kopenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cremona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Puma Biotechnology, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and
      safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR
      mutations or with EGFR gene amplification.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01953926</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Puma Biotechnology, Clinical Operations</name>
      <address />
      <phone>(424) 248-6500</phone>
      <fax />
      <email>ClinicalTrials@pumabiotechnology.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>